Samantha DiGrande

January 03, 2018

In 2017, the FDA more than doubled the number of drugs it approved compared with the previous year, with 46 novel medicines receiving the FDA’s endorsement in 2017.

January 01, 2018

The Psoriasis Stratification to Optimize Relevant Therapy (PSORT) study assessed real-world levels of self-reported non-adherence to traditional systemic and biologic therapies used for psoriasis, and evaluated psychological and biomedical factors associated with non-adherence using multivariable analyses.

December 31, 2017

There are a variety of biologics available for the treatment of psoriasis; our latest infographic provides examples of each type.

December 29, 2017

In 2008, tbo-filgrastim (Granix) was approved as a biosimilar in Europe. In 2012, it was approved in the United States as a follow-on biologic product to filgrastim. Tbo-filgrastim was less expensive than filgrastim, and clinical information and expert opinion supported similarity between the products. This led the pharmacy and therapeutics committee of a major US health system to approve tbo-filgrastim as the preferred granulocyte-colony stimulating factor (G-CSF) product in March 2014.

December 28, 2017

Elan Rubinstein, PharmD, MPH, voiced his frustration with the lack of presence the pharmacy profession has had in the negotiations of repealing and replacing the Affordable Care Act.

December 26, 2017

A recently published review appearing in the International Journal of Molecular Sciences, looks at the factors influencing psoriasis severity and the indications for systematic treatments.

December 22, 2017

Biologics are the most expensive drug category in the United States. A recent study, published in the Journal of Managed Care and Specialty Pharmacy, investigated how American health systems are reacting to the introduction of biosimilars into the marketplace, and described real-world implementation strategies.

December 21, 2017

JHL Biotech, a biopharmaceutical startup based in Taiwan, announced yesterday that it has submitted a phase 1 clinical trial application to the Dutch Healthcare Authority for its proposed dornase alfa biosimilar, JHL1922, to improve pulmonary function in patients with cystic fibrosis.

December 21, 2017

Hikma Pharmaceuticals Plc. announced yesterday that it has reached a licensing agreement with Republic of Korea-based Celltrion for its rituximab biosimilar, Truxima, referenced on MabThera.

December 19, 2017

Fresenius Kabi, a subsidiary of the German-based Fresenius SE and Co. KFaA, announced yesterday that its Marketing Authorization Application for MSB11022, an adalimumab (Humira) biosimilar candidate, was submitted and accepted for review by the European Medicines Agency (EMA).